Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

Alessandra Vergori (), Alessandro Cozzi Lepri, Stefania Cicalini, Giulia Matusali, Veronica Bordoni, Simone Lanini, Silvia Meschi, Roberta Iannazzo, Valentina Mazzotta, Francesca Colavita, Ilaria Mastrorosa, Eleonora Cimini, Davide Mariotti, Lydia De Pascale, Alessandra Marani, Paola Gallì, AnnaRosa Garbuglia, Concetta Castilletti, Vincenzo Puro, Chiara Agrati, Enrico Girardi, Francesco Vaia and Andrea Antinori
Additional contact information
Alessandra Vergori: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Alessandro Cozzi Lepri: Institute for Global Health, UCL
Stefania Cicalini: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Giulia Matusali: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Veronica Bordoni: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Simone Lanini: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Silvia Meschi: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Roberta Iannazzo: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Valentina Mazzotta: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Francesca Colavita: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Ilaria Mastrorosa: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Eleonora Cimini: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Davide Mariotti: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Lydia De Pascale: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Alessandra Marani: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Paola Gallì: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
AnnaRosa Garbuglia: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Concetta Castilletti: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Vincenzo Puro: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Chiara Agrati: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Enrico Girardi: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Francesco Vaia: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Andrea Antinori: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS

Nature Communications, 2022, vol. 13, issue 1, 1-13

Abstract: Abstract In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count 2 log2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32263-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32263-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32263-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().